Currently, there are 382.00M common shares owned by the public and among those 336.20M shares have been available to trade.
However, the script later moved the day high at 113.70, down -2.69%. The company’s stock has a 5-day price change of 2.19% and 13.19% over the past three months. MRNA shares are trading 8.00% year to date (YTD), with the 12-month market performance down to -28.81% lower. It has a 12-month low price of $62.55 and touched a high of $163.24 over the same period. MRNA has an average intraday trading volume of 4.45 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.21%, 8.68%, and 6.73% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Moderna Inc (NASDAQ: MRNA) shares accounts for 65.86% of the company’s 382.00M shares outstanding.
It has a market capitalization of $41.13B and a beta (3y monthly) value of 1.62. The earnings-per-share (ttm) stands at -$12.41. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.71% over the week and 4.52% over the month.
Earnings per share for the fiscal year are expected to increase by 41.70%, and 27.46% over the next financial year.
Looking at the support for the MRNA, a number of firms have released research notes about the stock. HSBC Securities stated their Reduce rating for the stock in a research note on February 26, 2024, with the firm’s price target at $75-$86. Oppenheimer coverage for the Moderna Inc (MRNA) stock in a research note released on January 02, 2024 offered a Outperform rating with a price target of $142. Canaccord Genuity was of a view on November 29, 2023 that the stock is Hold, while HSBC Securities gave the stock Hold rating on November 03, 2023, issuing a price target of $89- $69. Deutsche Bank on their part issued Sell rating on November 02, 2023.
